Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved pembrolizumab, marketed as Keytruda by Merck, for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of at least 1.
The approved use covers a perioperative pattern: pembrolizumab as neoadjuvant treatment, then continued after surgery as adjuvant treatment with radiotherapy, with or without cisplatin, and then as a single agent.
For oncology systems, this type of approval is operationally important because it links testing, surgery, radiotherapy, systemic therapy and follow-up into one coordinated treatment pathway.
Why It Matters
Cancer drug approvals increasingly reshape the whole care pathway, not just one line of metastatic treatment.
What to Watch
Watch implementation in surgical oncology teams, PD-L1 testing practice and real-world tolerance when immunotherapy is combined with surgery and radiotherapy.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAImmunotherapyHead and Neck CancerOncology